{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:27:03Z","timestamp":1781270823609,"version":"3.54.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","nucmedbio.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.nucmedbio.2017.04.007","type":"journal-article","created":{"date-parts":[[2017,5,3]],"date-time":"2017-05-03T03:16:59Z","timestamp":1493781419000},"page":"55-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["VPAC1 Targeted 64 Cu-TP3805 kit preparation and its evaluation"],"prefix":"10.1016","volume":"51","author":[{"given":"Sushil K.","family":"Tripathi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard J.","family":"Trabulsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"McCue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Intenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Gomella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew L.","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2017.04.007_bb0005","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1021\/cr900361p","article-title":"Peptides and peptide hormones for molecular imaging and disease diagnosis","volume":"110","author":"Lee","year":"2010","journal-title":"Chem Rev"},{"key":"10.1016\/j.nucmedbio.2017.04.007_bb0010","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1021\/mp500173s","article-title":"Positron emission tomography image-guided drug delivery: current status and future perspectives","volume":"11","author":"Chakravarty","year":"2014","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nucmedbio.2017.04.007_bb0015","first-page":"405","article-title":"Dual tracer imaging of SPECT and PET probes in living mice using a sequential protocol","volume":"2","author":"Chapman","year":"2012","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2017.04.007_bb0020","doi-asserted-by":"crossref","first-page":"13803","DOI":"10.1039\/c2dt31880f","article-title":"Copper-64 labelling of triazacyclononane-triphosphinate chelators","volume":"41","author":"Simecek","year":"2012","journal-title":"Dalton Trans"},{"key":"10.1016\/j.nucmedbio.2017.04.007_bb0025","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.2967\/jnumed.109.061846","article-title":"The advantages of nanoparticles for PET","volume":"50","author":"Welch","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2017.04.007_bb0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/138161207779313768","article-title":"Copper chelation chemistry and its role in copper radiopharmaceuticals","volume":"13","author":"Wadas","year":"2007","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.nucmedbio.2017.04.007_bb0035","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.nucmedbio.2008.12.008","article-title":"(64)Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity","volume":"36","author":"Wei","year":"2009","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2017.04.007_bb0040","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1039\/B704360K","article-title":"Metal complexes of cyclen and cyclam derivatives useful for medical applications: a discussion based on thermodynamic stability constants and structural data","author":"Delgado","year":"2007","journal-title":"Dalton Trans"},{"key":"10.1016\/j.nucmedbio.2017.04.007_bb0045","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0003-2697(85)90653-0","article-title":"Copper chelates as probes of biological systems: stable copper complexes with a macrocyclic bifunctional chelating agent","volume":"148","author":"Moi","year":"1985","journal-title":"Anal Biochem"},{"key":"10.1016\/j.nucmedbio.2017.04.007_bb0050","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1021\/cr980451q","article-title":"Radiometal-labeled agents (non-technetium) for diagnostic imaging","volume":"99","author":"Anderson","year":"1999","journal-title":"Chem Rev"},{"key":"10.1016\/j.nucmedbio.2017.04.007_bb0055","doi-asserted-by":"crossref","first-page":"6540","DOI":"10.1021\/ja01051a091","article-title":"Macrocyclic effect on the stability of copper(II) tetramine complexes","volume":"91","author":"Dale","year":"1969","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.nucmedbio.2017.04.007_bb0060","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1039\/B808831D","article-title":"Synthesis and characterization of the copper(II) complexes of new N2S2-donor macrocyclic ligands: synthesis and in vivo evaluation of the (64)Cu complexes","author":"Papini","year":"2009","journal-title":"Dalton Trans"},{"key":"10.1016\/j.nucmedbio.2017.04.007_bb0065","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1021\/jm030383m","article-title":"Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes","volume":"47","author":"Boswell","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2017.04.007_bb0070","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1021\/jm0103817","article-title":"Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands","volume":"45","author":"Sun","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2017.04.007_bb0075","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/bc990167l","article-title":"In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver","volume":"11","author":"Bass","year":"2000","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2017.04.007_bb0080","first-page":"1284","article-title":"In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy","volume":"44","author":"Lewis","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2017.04.007_bb0085","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1089\/cbr.2010.0820","article-title":"In vitro and in vivo evaluation of (6)(4)Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas","volume":"25","author":"Kumar","year":"2010","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2017.04.007_bb0090","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1021\/mp300610s","article-title":"Fibrin-targeted PET probes for the detection of thrombi","volume":"10","author":"Ciesienski","year":"2013","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nucmedbio.2017.04.007_bb0095","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1039\/b925128f","article-title":"Bis(thiosemicarbazones) as bifunctional chelators for the room temperature 64-copper labeling of peptides","volume":"39","author":"Hueting","year":"2010","journal-title":"Dalton Trans"},{"key":"10.1016\/j.nucmedbio.2017.04.007_bb0100","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.2967\/jnumed.112.114876","article-title":"VPAC1 receptors for imaging breast cancer: a feasibility study","volume":"54","author":"Thakur","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2017.04.007_bb0105","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2967\/jnumed.109.069542","article-title":"Imaging spontaneous MMTVneu transgenic murine mammary tumors: targeting metabolic activity versus genetic products","volume":"51","author":"Thakur","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2017.04.007_bb0110","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2967\/jnumed.107.043703","article-title":"PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer","volume":"49","author":"Zhang","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2017.04.007_bb0115","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.regpep.2007.06.008","article-title":"Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro\/in vivo evaluation","volume":"144","author":"Zhang","year":"2007","journal-title":"Regul Pept"},{"key":"10.1016\/j.nucmedbio.2017.04.007_bb0120","first-page":"1381","article-title":"PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog","volume":"45","author":"Thakur","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2017.04.007_bb0125","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.urology.2015.10.012","article-title":"VPAC1 Targeted (64)Cu-TP3805 Positron Emission Tomography Imaging of Prostate Cancer: Preliminary Evaluation in Man","volume":"88","author":"Tripathi","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.nucmedbio.2017.04.007_bb0130","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0304-3835(98)00125-6","article-title":"Stannous chloride and the glucoheptonic acid effect: study of a kit used in nuclear medicine","volume":"130","author":"Assis","year":"1998","journal-title":"Cancer Lett"},{"key":"10.1016\/j.nucmedbio.2017.04.007_bb0135","first-page":"3105","article-title":"Vasoactive intestinal peptide\/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin","volume":"60","author":"Reubi","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2017.04.007_bb0140","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2559.2011.04007.x","article-title":"Precursors of prostate cancer","volume":"60","author":"Bostwick","year":"2012","journal-title":"Histopathology"},{"key":"10.1016\/j.nucmedbio.2017.04.007_bb0145","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4111\/kju.2012.53.5.297","article-title":"High-grade prostatic intraepithelial neoplasia","volume":"53","author":"Klink","year":"2012","journal-title":"Korean J Urol"},{"key":"10.1016\/j.nucmedbio.2017.04.007_bb0150","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/pros.21291","article-title":"Elevated expression of cancer-associated proliferating cell nuclear antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer","volume":"71","author":"Wang","year":"2011","journal-title":"Prostate"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805117300719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805117300719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T01:27:24Z","timestamp":1535851644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805117300719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":30,"alternative-id":["S0969805117300719"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2017.04.007","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"VPAC1 Targeted 64Cu-TP3805 kit preparation and its evaluation","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2017.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}